Indexed maximal left atrial volume predicts response to cardiac resynchronization therapy by Rossi, Luca et al.
International Journal of Cardiology 168 (2013) 3629–3633
Contents lists available at ScienceDirect
International Journal of Cardiology
j ourna l homepage: www.e lsev ie r .com/ locate / i j ca rdIndexed maximal left atrial volume predicts response to cardiac
resynchronization therapy
Luca Rossi a,1, Alessandro Malagoli a,⁎, Massimo Piepoli a,2, Francesco Franchi b,3, Vincenzo Malavasi b,4,
Edoardo Casali b,5, Guido Rusticali a,6, Giovanni Quinto Villani a,6
a Department of Cardiology, “Guglielmo da Saliceto” Hospital, Piacenza, Via Taverna 49, 29100 Piacenza, Italy
b Department of Cardiology, Policlinico Hospital, Modena and Reggio Emilia University, Modena, Italy⁎ Corresponding author. Tel.: +39 0523 303221; fax:
E-mail addresses: rossi_luca@alice.it (L. Rossi), ale.m
(A. Malagoli), m.piepoli@ausl.pc.it (M. Piepoli), francesc
nanni.malavasi@gmail.com (V. Malavasi), edoardocasali
g.rusticali@ausl.pc.it (G. Rusticali), g.villani@ausl.pc.it (G
1 Tel.: +39 0523 303221; fax: +39 0523 303220.
2 Tel.: +39 0523 303222; fax: +39 0523 303220.
3 Tel.: +39 059 4225459; fax: +39 059 4224323.
4 Tel.: +39 059 4225463; fax: +39 059 4224323.
5 Tel.: +39 059 4225462; fax: +39 059 4224323.
6 Tel.: +39 0523 303215; fax: +39 0523 303220.
0167-5273/$ – see front matter © 2013 Elsevier Ireland
http://dx.doi.org/10.1016/j.ijcard.2013.05.028a b s t r a c ta r t i c l e i n f oArticle history:
Received 19 September 2012
Received in revised form 29 January 2013
Accepted 4 May 2013
Available online 29 May 2013
Keywords:
Left atrial volume
Cardiac resynchronization therapy (CRT)
Chronic heart failure
Aims: Cardiac resynchronization therapy (CRT) has shown morbidity and mortality beneﬁts in patients with
advanced congestive heart failure (HF). Since about one-third of the patients did not appear to respond to CRT,
it would seem reasonable to try to identify patients more accurately before implantation. Left atrial (LA) dimen-
sion has been proposed as a powerful outcome predictor in patients with heart disease. Accordingly, the aim of
this study is to prospectively assess the predictive value of LA for selecting CRT responders.
Methods: Fifty two consecutive patients with refractory HF, sinus rhythm and left bundle branch block were
enrolled in the study andplanned for CRT implantation. Clinical and echocardiographic evaluationswere performed
before CRT implantation and after 6 months. Three LAvolumes indexed to body surface area (iLAV)were computed
to evaluate the LA complexity: maximal LAV (iLAVmax), LAV just before atrial systole (iLAVpre), and minimal LAV
(iLAVpost). CRT responders were deﬁned as those who presented a reduction of >10% in LVESVi at 6-month
follow-up.
Results: Responders (63%) and nonresponders (37%) had similar baseline clinical characteristics and pre-
implantation LV volumes. However, baseline LA volumes were signiﬁcantly associated with the extent of LV
reverse remodeling: in particular, baseline iLAVmax was remarkably lower in responders than in nonresponders
(50.2 ± 14.1 ml/m2 vs 65.8 ± 15.7 ml/m2, p = 0.001) resulting predictive for CRT response.
Conclusion: Patients with small iLAV result as better responders to CRT than larger one. iLAVmax is an independent
predictor of LV reverse remodeling and allows to indentify the best candidates for CRT.© 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Cardiac resynchronization therapy (CRT) has become an effective
treatment modality in patients with advanced congestive heart failure
(HF) and prolongs survival compared to optimal medical therapy
alone [1,2]. However, about 30% of patients fail to respond to this
therapy, realizing a growing interest toward the identiﬁcation of
potential responders to CRT before implantation [3]. Recently, several
echocardiographic measurements of ventricular dyssynchrony have





Ltd. All rights reserved.To date the role of left atrium (LA) to predict response to CRT has
not yet been evaluated, although LA size has been suggested as a
powerful outcome predictor in patients with heart disease [4–6].
Moreover, LA size expresses the chronicity of exposure to abnormal
ﬁlling pressures and has been proposed in a retrospective analysis as a
predictor of mortality after CRT in patients with advanced HF [7]. Ac-
cordingly, the purpose of the present study was to prospectively assess
the predictive value of LA for selecting CRT responders.
2. Methods
2.1. Patient selection and study protocol
From the Cardiology Department of Piacenza Hospital andModena University Hospital
ﬁfty two consecutivepatientswith refractoryHF, left bundle branchblock and sinus rhythm
were prospectively enrolled in the study before CRT implantation. Patients were classiﬁed
as havingHFof ischemic or nonischemic etiologybased onahistoryofmyocardial infarction
or based on objective evidence of coronary artery disease as assessed with coronary angi-
ography. The criteria for CRT implantation were based according to the established inter-
national guidelines: symptomatic patients (NYHA functional class II or more), left
ventricular ejection fraction (LVEF) less than 35%, QRS duration > 120 ms (>150 ms if
NYHA functional class II) although on optimal pharmacologic therapy, including diuretics,
β-blockers, and angiotensin converting enzyme inhibitors or angiotensin receptor
Table 1
Demographic and baseline criteria (n = 52).
Age (yrs) 67.1 ± 10.2
Gender (M/F) 38/14
Systemic hypertension 15 (29%)
Diabetes mellitus 14 (27%)
GFR (ml/min/1.73 m2) 68 ± 21
PR interval (ms) 202 ± 30







ACE inhibitors/ARBs 50 (97%)
Diuretics 41 (79%)
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symptomatic bradyarrhythmias, previous history of atrial arrhythmias, pregnancy,
myocardial infarction or coronary interventionwithin 3 months of enrollment, or a signif-
icant comorbid illness deﬁned as severe obstructive pulmonary disease requiring chronic
supplementation of oxygen, severe renal failure (creatinine clearance b 30 ml/min),
malignancy, or medically refractory anginal symptoms.
Patients meeting inclusion criteria underwent a baseline evaluation prior to CRT
that included NYHA functional classiﬁcation, quality-of-life (QOL) assessment with
the Minnesota Living with Heart Failure Questionnaire and resting two-dimensional
Doppler echocardiographic study. At 6-month follow-up the same echocardiographic
and clinical parameters were reassessed. The study complies with the Declaration of
Helsinki, the study protocol was approved by the regional ethics committee of our in-
stitutions, and informed consent was obtained from each patient.
2.2. Device implantation
All ﬁfty two patients underwent successful implantation of a biventricular device.
The LV pacing lead was inserted by a transvenous approach through the coronary sinus
to target lateral or posterolateral cardiac vein; in one patient the target vein was
unavailable, so anterior vein was used. One day after implantation, the LV lead position
was assessed from a chest X-ray using the lateral views. The right atrial and ventricular
leads were positioned conventionally in right atrial appendage and in right ventricular
apex respectively. Choices of CRT devices included biventricular deﬁbrillators in 42
patients (Concerto II from Medtronic Inc.; Contak Renewal 4 from Boston scientiﬁc;
Atlas II HF from St. Jude Medicals) and biventricular pacemakers in 10 patients (InSync III
from Medtronic Inc.; Contak Renewal TR2 from Boston scientiﬁc; Frontier II from St. Jude
Medicals). No AVDdynamicmodewas set and no AVdelay optimization guided by echocar-
diography was performed after device implantation.
2.3. Echocardiography
Transthoracic echocardiography was performed with the subjects at rest in the left
lateral position with commercially available ultrasound equipment (Vivid 7, General
Electric and Acuson Sequoia c512, Siemens Medical). Images were obtained using a
3.5-MHz transducer, at a depth of 16 cm in the parasternal and apical views (standard
long-axis, two-chamber and four-chamber images) and measurements were performed
after a 10-minute run-in period for stabilization and equilibration.
2.3.1. LV and mitral valve evaluation
The LV volumes and the LVEFwere calculated from the apical two- and four-chamber
images using the biplane Simpson's rule. Values were indexed to body surface area calcu-
lated using the Du Bois and Du Bois Formula [8]. LV reverse remodeling was computed as
LV end-systolic volume (LVESVi) change between baseline and 6-month follow-up values
(ΔLVESVi). Inter-ventricular mechanical delay (IVMD) was calculated as the absolute dif-
ference in the LV and right ventricular pre-ejection times, with≥40 ms IVMD regarded as
a signiﬁcant delay. LV dyssynchrony was assessed by septal-to-lateral delay (Ts-LS)
deﬁned as described previously [9]. The ratio between peak early (E) and late (A) diastolic
LV ﬁlling velocities was used as standard indices of LV diastolic function [10]. LV longitu-
dinal functionwas explored by pulsed TissueDoppler imaging, placing the sample volume
at the level of mitral septal annulus from the apical fourchamber view [11]. Mean peak
early diastolic (E′) annular velocities were measured for 3 consecutive beats and aver-
aged. Mean E/E′ ratio was also calculated as load-independent marker of ventricular dia-
stolic relaxation [12]. Mitral regurgitation (MR) severity was graded according to the
current guidelines [13]. LV responders to CRT were deﬁned as those patients who
presented a reduction of >10% in LVESVi at 6-month follow-up, whereas those with a
lesser degree of reduction of 10% were deﬁned as nonresponders [14].
2.3.2. LA evaluation
Anteroposterior LA diameter (iLAd) was assessed by M-mode scan in parasternal
long axis view. LA volumes and LA emptying fraction were calculated from the apical
two- and four-chamber images using the biplane Simpson's rule and were indexed
to body surface area [8].
In order to evaluate the complexity of LA function we speciﬁed three atrial phases.
The ﬁrst is the reservoir phase: during ventricular systole and isovolumic relaxation
blood arrive into LA from pulmonary venous return; in this phase LA stores energy in
the form of pressure. The second is the passive phase: after mitral valve opening, in
the early phase of ventricular diastole, the LA transfers blood into the LV because of
pressure gradient, so blood ﬂows passively from the pulmonary veins into the left ventricle.
Finally in the contractile phase the LA systole serves to augment the LV stroke volume.
The following left atrial volume (LAV) parameters were recorded in order to
completely describe the LA contribution:
– Maximal LAV at ventricular end-systole where LA size is maximal (iLAVmax),
– LAV just before atrial systole (iLAVpre),
– Minimal LAV after atrial systole (iLAVpost).
Moreover, left atrial emptying fractions (LAEF) were derived from LA volumes and
calculated as follows:
– Total LA emptying volume (LAEFtot): [(iLAVmax − iLAVpost) / iLAVmax] × 100,
– LA passive emptying volume (LAEFpas): [(iLAVmax − iLAVpre) / iLAVmax] × 100,
– LA active emptying volume (LAEFcon): [(iLAVpre − iLAVpost) / iLAVpre] × 100.2.4. Statistical analysis
Statistical analysis was conducted using Package for Social Sciences version 17.0 for
Windows (SPSS Inc., Chicago, IL, USA) and Medcalc 7.3. Comparison of the continuous
parametric variables between baseline and 6-month follow-up was performed using a
paired sample t test or the χ2 test for the ordinal variables. Unpaired t test was used to
compare the echocardiographic parameters between responders and nonresponders. Lo-
gistic regression analysis was used to identify univariate and multivariable predictors of
CRT response. For the univariable models, p-value ≤ 0.10 was considered signiﬁcant
and the corresponding variable was included in the multivariable model. The odds ratio
(OR) and 95% conﬁdence interval (CI) are shown. All parametric data were expressed as
mean ± SD. A p-value b0.05 was considered statistically signiﬁcant.3. Results
3.1. Repeatability and reproducibility of measurements
Reproducibility of our laboratories has beenpublished previously [15].
Brieﬂy, for iLAVmax assessment intra-observer variabilitywas 4.8 ± 1.6%
and inter-observer was 6.7 ± 3.2%; for LVEDVi, intra-observer variability
was 5.7 ± 4.4% and inter-observer was 8.3 ± 4.6% both indicating out-
standing reliability.3.2. Study population
Baseline characteristics of the overall population are presented in
Table 1. Ischemic heart disease was present in 44% of patients; 46% of
patients were in NYHA class II, 50% in class III and 4% in class IV. Almost
all patients were treated with a beta-blocker (92%) and with ACE-
inhibitor or ARB (97%), 79% of patients had a diuretics. All patients
had severe LV dilation and eleven patients (21%) presented severe MR.3.3. Clinical and echocardiographic improvement after CRT
At 6-month follow-up, there was an improvement of clinical status
for the overall population, namelyNYHA functional class andMinnesota
Living With Heart Failure QOL score. CRT resulted in a signiﬁcant LA
(mean iLAVmax from 55 ± 16.4 ml/m2 to 50.3 ± 19 ml/m2, p 0.006)
and LV reverse remodeling (mean LVESVi from 94.7 ± 52.1 ml/m2 to
72.9 ± 54.1 ml/m2, p b 0.001) leading to an increase in both systolic
function. Moreover, a signiﬁcant reduction of MR and QRS duration
was observed (Table 2). Biventricular pacing percentagewas accurately
assessed through device counters' analysis performed at the 6-month
visit: a percentage of biventricular pacing > 85% was observed in all
patients and no atrial or ventricular arrhythmias were recorded.
During follow-up no patient died or was hospitalized for worsening
heart failure as well for device-related problems.
Table 2
Clinical status and echocardiographic parameters at baseline and 6-month follow-up.
All patients (n = 52)
baseline
All patients (n = 52)
6-month follow-up
p value
QRS interval (ms) 166 ± 20 137 ± 22 b0.001
NYHA functional class 2.6 ± 0.6 1.9 ± 0.6 b0.001
Qol score 36 ± 17 21 ± 16 b0.001
LVEDVi (ml/m2) 121.7 ± 53.5 103.6 ± 61.8 b0.001
LVESVi (ml/m2) 94.7 ± 52.1 72.9 ± 54.1 b0.001
LVEF (%) 22.2 ± 9.3 29.6 ± 10.1 b0.001
Mitral regurgitation:
EROA (mm2) 27 ± 3 15 ± 3 b0.001
R Vol (ml) 42 ± 4 22 ± 3 b0.001
E/A 1.46 ± 0.32 1.02 ± 0.24 0.01
E/E′ 21 ± 5 15 ± 8 b0.001
iLA diameter (mm/m2) 34.8 ± 4.1 34.2 ± 3.9 0.34
iLAVmax (ml/m2) 55.8 ± 16.4 50.3 ± 19 0.006
iLAVpre (ml/m2) 47 ± 15.2 41.4 ± 17.4 0.003
iLAVpost (ml/m2) 38.7 ± 15.3 30.3 ± 18 b0.001
LAEFtot (%) 31.9 ± 13.7 42.8 ± 16 b0.001
LAEFpas (%) 15.8 ± 9.2 18.3 ± 10.4 0.17
LAEFcon (%) 19.1 ± 13.1 29.5 ± 18.4 0.001
EROA = effective regurgitant oriﬁce area; R Vol = regurgitant volume.
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At 6-month follow-up, thirty three (63%) patients showed a reduc-
tion of >10% in LVESVi (mean reduction: −28.5 ± 33.7 ml/m2) and
were therefore classiﬁed as responders to CRT; nineteen (37%) patients
had a reduction of ≤10% in LVESVi and were therefore classiﬁed as
nonresponders to CRT. At baseline, clinical characteristics as well as
LV volumes were similar between responders and nonresponders
(Table 3). However, baseline LAV measurements were signiﬁcantly
associated with the extent of LV reverse remodeling (Table 3): CRT
responders displayed a signiﬁcantly lower baseline iLAVmax, iLAVpre
and iLAVpost compared to CRT nonresponders. Baseline LAEFtot and
LAEFcon in the responders were greater, although not statistically
signiﬁcant. However, baseline LAEFpas and baseline LA diameter were
similar between responders and nonresponders.
Finally, the prevalence of baseline echocardiography dyssynchrony
was higher in the responders, although this difference was not statisti-
cally signiﬁcant.Table 3






Age (yrs) 67.6 ± 11.4 66.5 ± 10.2 0.54
QRS interval (ms) 169 ± 19 162 ± 21 0.26
NYHA functional class 2.63 ± 0.6 2.59 ± 0.6 0.81
Qol score 36 ± 19 37 ± 18 0.84
LVEDVi (ml/m2) 115.3 ± 47.2 135.8 ± 47.3 0.19
LVESVi (ml/m2) 90 ± 42 103.9 ± 64.6 0.43
LVEF (%) 22.3 ± 9.3 25.8 ± 9.3 0.22
IVMD (ms) 52 ± 34 43 ± 31 0.08
Ts-LS (ms) 49 ± 37 42 ± 42 0.12
Mitral regurgitation
EROA (mm2) 26 ± 2 29 ± 3 0.45
R Vol (ml) 41 ± 4 43 ± 5 0.65
E/A 1.44 ± 0.29 1.46 ± 0.24 0.48
E/E′ 20 ± 6 21 ± 8 0.72
iLA diameter (mm/m2) 34.3 ± 4.3 35.3 ± 4.3 0.43
iLAVmax (ml/m2) 50.2 ± 14.1 65.8 ± 15.7 0.001
iLAVpre (ml/m2) 42.5 ± 13.4 55.1 ± 15.1 0.005
iLAVpost (ml/m2) 34.1 ± 13.8 46.8 ± 14.9 0.005
LAEFtot (%) 33.9 ± 12.6 28.4 ± 15.3 0.19
LAEFpas (%) 15.7 ± 8.2 16.1 ± 11.1 0.9
LAEFcon (%) 21.6 ± 12.7 14.8 ± 12.9 0.09
IVMD = Inter-ventricular mechanical delay; Ts-LS = time delay between time-to-peak
systolic velocities at the LV basal lateral and septal segments.
EROA = effective regurgitant oriﬁce area; R Vol = regurgitant volume.3.5. Left atrial volumes as predictors of CRT response
Differences between baseline LA volumes suggested their predictive
role for CRT response. Moreover, a linear correlationwas found between
baseline LA volumes and LV reverse remodeling. In particular, iLAVmax
showed the best relationship for LVESVi reduction (Fig. 1). A similar cor-
relation resulted for LAEFtot and LAEFcon; conversely, no correlation
was found between baseline iLAd and LAEFpas for LVESVi reduction.
Univariate regression analysis conﬁrmed these results: IVMD, Ts-LS,
QRS interval and smaller LA volumes were found to be predictors of
CRT response (Table 4). Variables in the univariate analysis with
p ≤ 0.10 were included in the multivariable model. iLAVmax resulted
the only parameter signiﬁcantly and independently predictive for CRT
response (p = 0.007).
To further investigate the ability of iLAVmax to predict LV reverse
remodeling, receiving operating characteristic (ROC) curve analysiswas
performed (Fig. 2). The areas under the curve (AUC) for the ROC curve
with iLAVmax used to predict LV reverse remodeling was 0.767 (95%
CI, 0.618–0.916; p b 0.01). Optimal sensitivity and speciﬁcity were
obtained at a cutoff level of 58 ml/m2 (71% and 74% respectively). An
iLAVmax value of 50 ml/m2 was 88% sensitive as predictor of CRT re-
sponse, although speciﬁcity decreased to 57%.
4. Discussion
In patients with HF and prolonged QRS duration, CRT provides
clinical beneﬁts and improvement of LV systolic function as a result of
LV reverse remodeling [16–18]. Thus, there is a strong clinical mandate
for the use of CRT in eligible patients that is supported by international
practice guidelines [19]. Although most treated patients show a beneﬁt
from CRT, nonresponders of this therapy have been consistently
observed in about one-third of patients [1].
Recently, several echocardiographic measurements of mechanical
dyssynchrony have been proposed to identify responders to CRT before
device implantation. However, the Predictors of Response to CRT
(PROSPECT) trial reported that no single echocardiographic measure-
ment of dyssynchrony can be recommended to improve patient selection
for CRT [20]. Currently, we are looking for some pre-implantation clinical
and echocardiographic parameters able to predict CRT response in order
to optimize the decision making.
LA is an asymmetric thin-walled structure and its size may increase
with pathological LV ﬁlling pressure, providing a simple noninvasive
assessment of the degree of LV diastolic dysfunction [21–24]. Recent
data suggest LA dilatation as a predictor of common cardiovascular out-
comes suchas atrialﬁbrillation, congestive HF, cardiovascular death and
stroke [4–6]. Nevertheless, the impact of LA size in patients with CRT
has not been fully evaluated. Shen et al. retrospectively showed the
pre-implantation LA enlargement as a predictor of mortality, but failed
to assess the LA predictive role for LV reverse remodeling after CRT
implantation [7]. Accordingly, our study is the ﬁrst to prospectively
demonstrate the predictive role of LA volume for CRT response and
we should conclude that more advanced is HF and larger is LA size,
therefore response to CRT will be unlikely. Furthermore, we propose
an iLAVmax cutoff value of 58 ml/m2 beyond that low probability of
CRT response is expected. This iLAVmax cutoff value is similar to
59 ml/m2 LAV index cutoff previously proposed by Shen et al.
Our study is the ﬁrst to analyze the predictive role of several LA
measurements for CRT response. LA dimension is usually measured
at the ventricular end-systole from the parasternal long-axis view.
However, it has been shown that LA antero-posterior diameter is an
inaccurate representation of its size, because LA may not dilate equally
along its three axes [25]. Recent data suggest that two-dimensional-
derived LA volume provides a more accurate measure of LA true size.
End-systolic LA volume from apical four-chamber view is the one
routinely measured in clinical practice. Nevertheless, a comprehen-
sive assessment of LA function as previously described is mandatory
Fig. 1. Linear correlation between baseline iLAVmax and LV reverse remodeling.
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LAEFtot represent the reservoir phase, iLAVpre and LAEFpas represent
the conduit phase, iLAVpost and LAEFcon represent the contractile
phase. We demonstrated the predictive role to CRT response for all LA
volumes; the best linear correlation was found for iLAVmax, likely as
expression of LV ﬁlling pressure over time. Indeed the contribution of
LA phasic function to LV ﬁlling is dependent on LV diastolic properties:
in the early diastolic dysfunction when abnormal relaxation occurs, the
relative contribution of LA contractile function to LV ﬁlling increases,
whereas the conduit function decreases. As LV ﬁlling pressure progres-
sively increases, the LA volume increase to the limits of atrial preloadTable 4
Predictors of CRT response.
OR 95% CI p value
Age (1-year increase) 1.02 0.96–1.08 0.54
Sex (male) 0.85 0.21–3.37 0.81
Ischemic etiology 0.75 0.22–2.49 0.64
QRS interval (ms) 1.12 1.03–1.20 0.09
NYHA functional class 1.13 0.42–3.06 0.8
Qol score 1.52 0.96–2.4 0.34
LVEDVi (ml/m2) 0.99 0.98–1.00 0.24
LVESVi (ml/m2) 0.99 0.98–1.01 0.37
LVEF (%) 0.94 0.90–0.98 0.46
IVMD (ms) 1.11 1.01–1.22 0.08
Ts-LS (ms) 1.06 1.02–1.10 0.07
Mitral regurgitation: EROA (mm2) 0.83 0.52–1.33 0.44
iLAd (mm/m2) 1.17 0.25–5.54 0.84
iLAVmax (mm/m2) 0.93 0.89–0.98 0.004
iLAVpre (ml/m2) 0.94 0.90–0.99 0.011
iLAVpost (ml/m2) 0.94 0.89–0.99 0.011
LAEFtot (%) 1.03 0.98–1.08 0.18
LAEFpas (%) 0.99 0.93–1.06 0.89
LAEFcon (%) 1.05 0.99–1.12 0.11
IVMD = Inter-ventricular mechanical delay; Ts-LS = time delay between time-to-peak
systolic velocities at the LV basal lateral and septal segments.
EROA = effective regurgitant oriﬁce area.reserve by the Frank–Starling mechanism. Conversely, LAEF is more
representative of the intrinsic atrial function and so less connected to
LV ﬁlling pressure, resulting worst related to CRT response.Fig. 2. Receiver operating characteristic curve of iLAVmax values as predictors of LV
reverse remodeling. AUC = area under the curve; SE = standard error; CI = conﬁdence
interval.
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This is a prospective noninvasive study with a small sample size,
investigating LA volume as a predictor of CRT response. Further
large-scale, multicenter studies collecting follow-up data are required
to conﬁrm our results. Furthermore, we performed the LA evaluation
just by volumes and empting fraction; however, we cannot deny that
newer echocardiographic technologies such as three-dimensional
speckle tracking might assess the LA function in a more proper way.
Another potential source of bias is the lack of a central echo core-lab;
nevertheless, this limitation is exceeded by the low variability between
the investigators who performed echocardiograms.
5. Conclusion
Patients with small LA volume result as better responders to CRT. In
particular, iLAVmax is an independent predictor of LV reverse remodeling
and allows to identify best candidates for CRT.
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